EMA HMPC Meeting Report – November 2022 EMA HMPC Meeting Report – November 2022 EMA’s Committee on Herbal Medicinal Products (HMPC) has published the report from their... EMA HMPC Meeting Report – November 2022
MHRA Publishes Marketing Authorisations Granted between 15 – 31 December 2022 MHRA Publishes Marketing Authorisations Granted between 15 – 31 December 2022 MHRA granted one OTC licence between 15 – 31... MHRA Publishes Marketing Authorisations Granted between 15 – 31 December 2022
EMA Management Board – December 2022 Meeting Highlights EMA Management Board – December 2022 Meeting Highlights The European Medicines Agency (EMA) has published the highlights from its Management... EMA Management Board – December 2022 Meeting Highlights
MHRA – October & November 2022 Licensing Time-based Performance Measures Published MHRA – October & November 2022 Licensing Time-based Performance Measures Published MHRA publish data on the expected time taken to... MHRA – October & November 2022 Licensing Time-based Performance Measures Published
Request for a Preliminary Ruling to the European Court of Justice (Case C-616/20) – Distinction between Medicinal Product and Cosmetic Product – Court Judgment Request for a Preliminary Ruling to the European Court of Justice (Case C-616/20) – Distinction between Medicinal Product and Cosmetic... Request for a Preliminary Ruling to the European Court of Justice (Case C-616/20) – Distinction between Medicinal Product and Cosmetic Product – Court Judgment
EMA Publishes Revision of Nitrosamine Q&A EMA Publishes Revision of Nitrosamine Q&A The European Medicines Agency has published an updated guidance on the... EMA Publishes Revision of Nitrosamine Q&A
The Future Strategy for Batch Testing of Medicinal Products in Great Britain – Outcome and Government Response The Future Strategy for Batch Testing of Medicinal Products in Great Britain – Outcome and Government Response The... The Future Strategy for Batch Testing of Medicinal Products in Great Britain – Outcome and Government Response
Proposal for Regulation of the European Parliament and of the Council on Fees and Charges Payable to EMA Adopted Proposal for Regulation of the European Parliament and of the Council on Fees and Charges Payable to EMA Adopted The... Proposal for Regulation of the European Parliament and of the Council on Fees and Charges Payable to EMA Adopted
SCHEER Final Opinion on Ibuprofen Published SCHEER Final Opinion on Ibuprofen Published The final SCHEER (Scientific Committee on Health, Environmental and Emerging Risks), Final Opinion on... SCHEER Final Opinion on Ibuprofen Published
MHRA Nitrosamines – Step 1 and 2 Submission Reminder MHRA Nitrosamines – Step 1 and 2 Submission Reminder MHRA has shared a letter which has been sent to all... MHRA Nitrosamines – Step 1 and 2 Submission Reminder
MHRA Publishes Marketing Authorisations Granted in November 2022 MHRA Publishes Marketing Authorisations Granted in November 2022 MHRA granted one licence in November 2022. Details of the marketing authorisation... MHRA Publishes Marketing Authorisations Granted in November 2022
EMA Highlights – 17th Industry Platform Meeting on Operation of EU Pharmacovigilance Legislation EMA Highlights – 17th Industry Platform Meeting on Operation of EU Pharmacovigilance Legislation The European Medicines Agency (EMA)... EMA Highlights – 17th Industry Platform Meeting on Operation of EU Pharmacovigilance Legislation